You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BET inhibitor

Showing 1 - 25 of 7,433
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute GVHD, Steroid Refractory GVHD Trial in Columbus (BRD4 Inhibitor PLX51107)

Recruiting
  • Acute Graft Versus Host Disease
  • Steroid Refractory Graft Versus Host Disease
  • BRD4 Inhibitor PLX51107
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Mar 24, 2022

Breast Carcinoma, Metastatic Malignant Tumor in the Brain, Metastatic Malignant Tumor in the Leptomeninges Trial in Chicago

Not yet recruiting
  • Breast Carcinoma
  • +2 more
  • Biospecimen Collection
  • +6 more
  • Chicago, Illinois
    Northwestern University
Nov 14, 2023

Advanced Malignant Solid Tumor, Advanced Ovarian Carcinoma, Metastatic Malignant Solid Tumor Trial (BET Bromodomain Inhibitor

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +7 more
  • Atlanta, Georgia
  • +2 more
Nov 3, 2022

Castrate Resistant Prostate Cancer, NUT Carcinoma Trial (EP31670)

Not yet recruiting
  • Castrate Resistant Prostate Cancer
  • NUT Carcinoma
  • (no location specified)
Aug 3, 2022

Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Pittsburgh (ZEN003694, Talazoparib)

Recruiting
  • Ovarian Cancer
  • +2 more
  • Pittsburgh, Pennsylvania
    University of Pittsburgh Medical Center
Apr 27, 2022

Metastatic Malignant Solid Tumor, Recurrent Malignant Solid Tumor, Recurrent Platinum-Resistant Ovarian Carcinoma Trial in

Recruiting
  • Metastatic Malignant Solid Neoplasm
  • +3 more
  • BET Bromodomain Inhibitor ZEN-3694
  • +2 more
  • Bethesda, Maryland
  • +4 more
Aug 16, 2022

Metastatic Malignant Solid Tumor, Metastatic NUT Carcinoma, Unresectable Malignant Solid Tumor Trial (Abemaciclib, BET

Suspended
  • Metastatic Malignant Solid Neoplasm
  • +3 more
  • Boston, Massachusetts
    Dana-Farber - Harvard Cancer Center LAO
Sep 17, 2022

Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid

Not yet recruiting
  • Recurrent Endometrial Carcinoma
  • +8 more
  • BET Bromodomain Inhibitor ZEN-3694
  • +7 more
  • (no location specified)
Jul 15, 2023

AML Including AML de Novo and AML Secondary to MDS, DLBCL Trial (Birabresib Dose 20 mg)

Terminated
Has Results
  • AML Including AML de Novo and AML Secondary to MDS
  • DLBCL
  • Birabresib Dose 20 mg
  • (no location specified)
Aug 23, 2022

Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8 Trial (drug,

Not yet recruiting
  • Metastatic Colorectal Adenocarcinoma
  • +2 more
  • BET Bromodomain Inhibitor ZEN-3694
  • +6 more
  • (no location specified)
Oct 25, 2023

Advanced Uveal Melanoma, Metastatic Uveal Melanoma, Unresectable Uveal Melanoma Trial (BRD4 Inhibitor PLX2853, Trametinib,

Not yet recruiting
  • Advanced Uveal Melanoma
  • +2 more
  • BRD4 Inhibitor PLX2853
  • +4 more
  • (no location specified)
Jan 9, 2023

Advanced Lymphoma, Advanced Malignant Solid Tumor, Advanced Pancreatic Carcinoma Trial in New Haven (BET Bromodomain Inhibitor

Recruiting
  • Advanced Lymphoma
  • +13 more
  • BET Bromodomain Inhibitor ZEN-3694
  • +2 more
  • New Haven, Connecticut
    Yale University Cancer Center LAO
Jun 29, 2022

Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor Trial in Boston, Galveston,

Suspended
  • Advanced Malignant Solid Neoplasm
  • +4 more
  • Boston, Massachusetts
  • +2 more
Oct 5, 2022

Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Triple-Negative Breast

Not yet recruiting
  • Anatomic Stage III Breast Cancer AJCC v8
  • +4 more
  • BET Bromodomain Inhibitor ZEN-3694
  • +3 more
  • (no location specified)
Jun 28, 2022

Hematopoietic and Lymphoid System Tumor, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Tumor Trial (BET

Not yet recruiting
  • Hematopoietic and Lymphoid System Neoplasm
  • +5 more
  • BET Bromodomain Inhibitor ZEN-3694
  • +6 more
  • (no location specified)
Apr 6, 2023

NUT Midline Carcinoma, Triple Negative Breast Cancer, NSCLC With Rearranged ALK Gene/Fusion Protein or KRAS Mutation Trial

Completed
Has Results
  • NUT Midline Carcinoma
  • +5 more
  • (no location specified)
Jan 7, 2021

Glioblastoma Multiforme Trial (Birabresib)

Terminated
Has Results
  • Glioblastoma Multiforme
  • (no location specified)
Jan 7, 2021

NUT Midline Carcinoma (NMC), Triple Negative Breast Cancer (TNBC), NSCLC (NSCLC) Trial (Birabresib)

Terminated
Has Results
  • NUT Midline Carcinoma (NMC)
  • +3 more
  • (no location specified)
Jan 7, 2021

Multiple Myeloma Trial in Australia, United Kingdom, United States (RO6870810, daratumumab)

Completed
  • Multiple Myeloma
  • Duarte, California
  • +11 more
Feb 6, 2020

Solid Tumor, Childhood, Lymphoma, Brain Tumor, Pediatric Trial in Canada, United States (BMS-986158, BMS-986378)

Recruiting
  • Solid Tumor, Childhood
  • +2 more
  • Boston, Massachusetts
  • +5 more
Dec 27, 2022

Advanced Malignant Tumors Trial in Guangzhou, Hangzhou (TQB3617)

Recruiting
  • Advanced Malignant Tumors
  • Guangzhou, Guangdong, China
  • +1 more
Feb 11, 2022

Metastatic NUT Carcinoma, Unresectable NUT Carcinoma Trial (Cisplatin, Etoposide, Etoposide Phosphate)

Withdrawn
  • Metastatic NUT Carcinoma
  • Unresectable NUT Carcinoma
  • (no location specified)
Sep 25, 2020

Advanced Lymphoma, Advanced Malignant Solid Tumor, Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma Trial (Entinostat,

Withdrawn
  • Advanced Lymphoma
  • +16 more
  • (no location specified)
Sep 25, 2020

Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis Trial in Worldwide (Pelabresib, Ruxolitinib, Placebo)

Recruiting
  • Myelofibrosis
  • +3 more
  • Birmingham, Alabama
  • +148 more
Oct 10, 2022

Advanced Solid Tumors Trial in Madrid ([14C]CC-90010, CC-90010)

Not yet recruiting
  • Advanced Solid Tumors
  • Madrid, M, Spain
  • +1 more
Dec 23, 2022